Navigation Links
EUSA Pharma Submits ERWINASE(R) Biologics License Application (BLA) for Treatment of Acute Lymphoblastic Leukemia
Date:11/9/2010

ecialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ERWINASE(R) (L-asparaginase derived from Erwinia chrysanthemi) for use in the treatment of acute lymphoblastic leukemia in patients with hypersensitivity to E. coli-derived asparaginase. ERWINASE is currently approved in a number of countries, including Canada, the UK and several European Union member states, and is supplied in the United States under a treatment IND.

EUSA Pharma submitted its ERWINASE BLA on a rolling basis, following receipt of Fast Track designation from the FDA. The completed BLA submission requests Priority Review status, which can reduce the regulatory assessment period to six months for major treatment advances. Additionally, the FDA has awarded ERWINASE orphan drug designation, which provides a seven-year period of market exclusivity upon approval.

Dr Tim Corn, EUSA Pharma's Chief Medical Officer, commented, "The submission of our ERWINASE BLA is a major step towards our goal of making this important therapy available as rapidly as possible. Many children with acute lymphoblastic leukemia develop allergy to current asparaginase products, and ERWINASE provides a key therapeutic alternative for this gravely ill group in several countries around the world. By applying for Priority Review status, we hope to shorten the period before EUSA can launch ERWINASE in the U.S., and reduce the time before physicians can provide this potentially life-saving drug to those who may benefit from it."

"Completing the BLA filing for ERWINASE marks a major strategic milestone for EUSA," said Bryan Morton, EUSA Pharma's President and Chief Executive Officer. "Based on new study results and existing clinical experience, we believe ERWINASE has the potential to enhance the treatment of acute lymphoblastic leukemia signific
'/>"/>

SOURCE EUSA Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
2. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
3. How IT Helps Solve Pharmas R&D Problems: in silico Drug Discovery
4. UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth
5. Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas
6. Tianyin Pharmaceutical Co., Inc. to Host First Quarter of Fiscal Year 2011 Earnings Conference Call on Thursday, November 11, 2010 at 9:00 a.m. ET
7. ShangPharma Announces Appointment of Benson Tsang as a Member of the Board of Directors and Audit Committee
8. NovaSperse(SM) Nanoparticle Innovator, PharmaNova, Inc., Awarded Four Government Grants Toward Development of New Therapeutic Products Under Congressional Qualifying Therapeutic Discovery Project Initiative
9. WuXi PharmaTech Awarded GLP Certificate from SFDA for Suzhou Toxicology Facility
10. EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist
11. Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)...   Cypher Genomics, Inc., the genome informatics ... Ravenel as chief technology officer. Ravenel has more ... and a proven track record of designing and architecting ... has been recognized as a top designer and architect ... industry-wide for delivering innovative products that operate at scale ...
(Date:10/1/2014)... 1, 2014   Royal Philips (NYSE: ... its eCareCoordinator and eCareCompanion telehealth applications have received ... Administration (FDA). A part of Philips Hospital to ... and eCareCompanion are focused on patient care within ... to be available through the cloud-based digital health ...
(Date:10/1/2014)... 1, 2014  CVS Health is thanking its 26,000 ... in changing the way health care is delivered to ... Company,s retail pharmacies, mail service pharmacies and specialty pharmacies ... company name to CVS Health to reflect our broader ... innovations needed to shape the future of health," said ...
Breaking Medicine Technology:Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3
... Aug. 30 Brothers blow the numbers away. ... short years ago and have never looked back. ... (Logo:   http://photos.prnewswire.com/prnh/20100817/INC5000LOGO ) (Logo:  http://www.newscom.com/cgi-bin/prnh/20100817/INC5000LOGO) ... provider of low cost ultrasound systems in the ...
... FALLS, N.Y., Aug. 30 Laerdal Medical has ... training since the company launched its famous Resusci ... extensive experience to bear as it launches its ... (Photo: http://photos.prnewswire.com/prnh/20100830/NY56743 ) (Photo: ...
Cached Medicine Technology:National Ultrasound Makes the Inc 5000 List for Third Year in a Row 2Laerdal Introduces SimMan Essential 2Laerdal Introduces SimMan Essential 3
(Date:10/1/2014)... October 01, 2014 Insuranceragents.info has ... a good life insurance plan for vulnerable family members. ... vulnerable family members. Providers in the family should always ... cause financial hardships for the rest of the family. ... policies. Families can benefit more from temporary coverage or ...
(Date:10/1/2014)... October 01, 2014 Phoseon Technology, the ... continues to expand the business worldwide. This rapid growth ... additional capacity for manufacturing efforts. The company has experienced ... five years and expects this growth to continue in ... technology gains worldwide adoption. , “We are very ...
(Date:10/1/2014)... A new genetic finding from Duke Medicine suggests that ... depression might also be hard-wired to gain weight when ... disease. , An estimated 13 percent of people, all ... and knowing this could help them reduce heart disease ... and stress management. , "Genetic susceptibility, psychosocial stress and ...
(Date:10/1/2014)... Jersey City, NJ (PRWEB) October 01, 2014 ... sticking with their intentions to lose weight and their dieting ... in unhealthy, fatty foods. Including hormone diet treatments ... not only allows patients to see fast and effective weight ... diet and begin forming healthy habits to maintain their weight ...
(Date:10/1/2014)... 2014 On Sept. 9, Chapín Coffee ... the Martha Stewart American Made Awards (MSAMAs), an annual ... country in the fields of crafts, design, food and ... a finalist in the MSAMAs, which celebrates entrepreneurs and ... improving local communities and changing the way we shop, ...
Breaking Medicine News(10 mins):Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2
... experimental vaccine developed by researchers at Cedars-Sinai Medical Center,s ... aggressive brain tumors and improves length of survival in ... presented in a poster session at the 47th Annual ... Patients with newly diagnosed glioblastoma multiforme, the most ...
... biologists at Cold Spring Harbor Laboratory (CSHL) have obtained ... an allosteric inhibitor in a subtype of the NMDA ... The newly discovered binding site -- a ... it is a potential target for drugs that can ...
... By Maureen Salamon HealthDay Reporter ... research in Illinois reveals that medical specialists refuse ... conditions six times more often than privately insured ... mothers of children with seven common health conditions ...
... , WEDNESDAY, June 15 (HealthDay News) -- Medical ... look beyond survival and plan for the future. But for ... researchers say. In fact, researchers from Penn State found ... each year in medical care costs than people who have ...
... 15, 2011 A University of Houston (UH) chemist who ... published papers in two high-impact journals this month. ... colleagues have developed two different materials that are both equally ... June issues of Chemical Communications ( ChemComm ) ...
... the journal Nature , scientists discovered an entirely new ... are significant because they may ultimately help researchers alter the ... dystrophy and many forms of cancer. The genetic ... tell a cell how to make a specific protein. Central ...
Cached Medicine News:Health News:Latest data from Cedars-Sinai vaccine study supports immune targeting of brain tumors 2Health News:Latest data from Cedars-Sinai vaccine study supports immune targeting of brain tumors 3Health News:CSHL structural biologists reveal novel drug binding site in NMDA receptor subunit 2Health News:Specialists Often Turn Away Kids With Public Insurance: Report 2Health News:Specialists Often Turn Away Kids With Public Insurance: Report 3Health News:Cancer Survivors Face High Health Costs Over Long Term: Report 2Health News:UH chemist developing materials to detect, repel E. coli 2Health News:Changing genetic 'red light' to green holds promise for treating disease 2Health News:Changing genetic 'red light' to green holds promise for treating disease 3
... sensitivity (threshold) testing provides clinically beneficial ... ophthalmic conditions. Dark adaptometry is useful ... retinal degenerations, senile miosis, high myopia, ... conditions, while whole-field scotopic sensitivity has ...
... The MFERG is available in conjunction with ... UTAS-E3000mf or EPIC-4000 or as a stand-alone ... visual electrodiagnostic test uses a software controlled ... to stimulate many areas of the retina ...
... Amplifier (UBA-4204) from LKC Technologies, ... amplification and complete electrical isolation ... problems of DC drifting, 50/60Hz ... make the amplifier ideal for ...
... to facilitate an arthrodesis, either by an ... cages allowing radicular compression by restoring the ... of the foramina, which in turn enhances ... major lumbar instabilities.,CC cages are made of ...
Medicine Products: